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Manuscript received August 5, 2015 and accepted November 11, 2015AbstractPatients in the early stage of hypertensive heart disease tend to have normal echocardiographic findings. The aim of this study
was to investigate whether pathology-specific echocardiographic morphologic and functional parameters can help to detect
subclinical hypertensive heart disease. One hundred ten consecutive patients without a history and medication for arterial
hypertension (AH) or other cardiac diseases were enrolled. Standard echocardiography and two-dimensional speckle-
tracking-imaging analysis were performed. Resting blood pressure (BP) measurement, cycle ergometer test (CET), and
24-hour ambulatory BP monitoring (ABPM) were conducted. Patients were referred to ‘‘septal bulge (SB)’’ group (basal-
septal wall thickness 2 mm thicker than mid-septal wall thickness) or ‘‘no-SB’’ group. Echocardiographic SB was found
in 48 (43.6%) of 110 patients. In this SB group, 38 (79.2%) patients showed AH either by CET or ABPM. In contrast, in the
no-SB group (n ¼ 62), 59 (95.2%) patients had no positive test for AH by CET or ABPM. When AH was solely defined by
resting BP, SB was a reasonable predictive sign for AH (sensitivity 73%, specificity 76%). However, when AH was confirmed
by CET or ABPM the echocardiographic SB strongly predicted clinical AH (sensitivity 93%, specificity 86%). In addition,
regional myocardial deformation of the basal-septum in SB group was significantly lower than in no-SB group (14  4% vs.
17  4%; P < .001). In conclusion, SB is a morphologic echocardiographic sign for early hypertensive heart disease.
Sophisticated BP evaluation including resting BP, ABPM, and CET should be performed in all patients with an accidental
finding of a SB in echocardiography. J Am Soc Hypertens 2016;10(1):70–80.  2016 The Authors. Published by Elsevier
Inc. on behalf of American Society of Hypertension. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Arterial hypertension (AH) has been well recognized as a
common risk factor for cardiovascular disease.1–5 However,
a great number of early hypertensive patients neverConflict of interest: None.
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http://dx.doi.org/10.1016/j.jash.2015.11.006experience any symptoms, and the awareness rate of AH
remains low in general. Thus, early diagnosis of AH re-
mains a challenge, particularly in a subclinical population.
It is known that left ventricular (LV) hypertrophy with
different remodeling patterns is one of the major cardiac
manifestations of hypertensive heart disease, and echocar-
diographic LV hypertrophy could be detected in 20% to
40% of patients with AH.7–10 However, there are often no
specific echocardiographic features for hypertensive
patients at the early stage of disease.11 Previous echocar-
diographic studies have described asymmetric septal hyper-
trophy with a localized septal thickening at the basal-midAmerican Society of Hypertension. This is an open access article
by-nc-nd/4.0/).
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or aortic valve stenosis.14,15 Basal-septal hypertrophy may
also occur in a subset of older normal subjects, with normal
wall thickness (WT) elsewhere, and is considered to be an
age-related anatomic variant.16,17 This morphologic echo-
cardiographic sign is termed as septal bulge (SB), sigmoid
septum, or discrete upper septal thickening or knuckle.18 A
large community-based population study reported that SB
was documented frequently in elderly individuals with
higher systolic blood pressure (SBP). It was shown that
the overall prevalence of SB was 1.5% and was markedly
higher (18%) in the eighth decades of life.18 Although path-
ologic and echocardiographic observations have indicated
that SB is a structural response in hypertensive
patients,19–21 the nature and significance of the SB in sub-
clinical AH was never investigated.
In addition, despite the fact that BP can be easily
measured, AH sometimes cannot be diagnosed due to the
underreported BP reading in the casual or self-measured
BP measurement.22 BP measurement with appropriate tools
is essential to diagnosing AH early as well as to guiding
AH management. It has been shown that, besides resting
BP measurement in the office, AH could be clinically diag-
nosed by 24-hour ambulatory BP monitoring (ABPM) as
well as exercise stress test in some resting normotensive in-
dividuals.1,23–25
In the present study, we prospectively screened a subset of
population without history and medication of AH as well as
other cardiac diseases. A sophisticated clinical assessment
for AH was conducted in these patients, including resting
BP measurement, cycle ergometer test (CET) and ABPM.
We investigated the prevalence of echocardiographic SB
and its relationship with AH. We speculate that SB might
represent an earlier structural adaption in response to pres-
sure overload before LV concentric hypertrophy in AH.
Methods
This study was initiated in February 2013. The study
subjects were selected from a group of 8208 consecutive
patients referred to the echocardiographic laboratory in
the University Hospital of W€urzburg between February
2013 and February 2014. The enrollment criteria included
(1) no history of AH and any heart diseases and (2) no his-
tory of medications for AH. A total of 154 eligible patients
were invited to take part in the AH screen study. Forty-four
patients, who refused to receive 24-hour ABPM or were un-
able to perform CET, were excluded. Finally, 110 patients
completed this study. The screening flowchart of the study
is shown in Figure 1. Standard echocardiographic examina-
tion was performed in all patients. Resting electrocardiog-
raphy (ECG), resting manual BP measurement, ABPM,
and CET (ECG/BP) were performed on the same day in
all patients. The study was approved by Local Ethics Com-
mittee at the University of W€urzburg and conducted inaccordance to the Declaration of Helsinki. Written
informed consent was obtained from all patients or their
guardians.
Brachial BP was measured at rest. Patients were seated
quietly for at least 5 minutes in a chair before the mea-
surement. At least 2 measurements were made in each pa-
tient. Afterward, CET was performed on an electrically
braked cycle ergometer (Ergometrics 900, Ergoline, Bitz,
Germany) with incremental loads at 50/75/100/150 Watts
(each stage for 3 minutes), until exhaustion. Brachial BP
was measured every 3 minutes interval during testing.
The testing was stopped when the targeted age-adjusted
heart rate was achieved, or when SBP increased to more
than 250 mm Hg, or when chest pain or arrhythmia
occurs.
After CET, 24-hour ABPM was performed using a digi-
tal oscillometric blood pressure device (Mobil-O-Graph
NG version 20, I.E.M., Germany). BP was measured every
15 minutes during the waking period (8 AM–12 PM) and
every 30 minutes during the sleeping period (12 PM–8
AM). The test was considered satisfactory when at least
70% of the BP readings were valid.
AH was suggested by resting BP: SBP  140 mm Hg or
diastolic BP (DBP)  90 mm Hg based on the mean of 2 or
more properly measured seated BP.1,3 Patients were defined
as AH with positive CET results (SBP  200 mm Hg at 50,
75, or 100 Watts26) or positive ABPM results (mean SBP >
135 mm Hg or DBP > 85 mm Hg during the waking period
and SBP > 120 mm Hg or DBP > 70 mm Hg during the
sleeping period1) or both.
The classification of high BP was defined as: normal,
SBP < 120, and DBP < 80 mm Hg; high-normal,
SBP ¼ 120–139 or DBP ¼ 90–99 mm Hg; stage 1 hyper-
tension, SBP ¼ 140–159 or DBP ¼ 90–99 mm Hg; stage 2
hypertension, SBP  160 or DBP  100 mm Hg.1,3
A standard transthoracic echocardiographic examination
was performed (GE, Vingmed, Horten, Norway). Standard
two-dimensional (2D) images and Doppler recordings were
obtained according to guidelines.27 All offline measure-
ments were performed in a remote workstation (EchoPAC
version 112, GE, Horten, Norway). LVend-diastolic dimen-
sion (LVEDD), end-diastolic WT of the mid septum (IVSd)
and the posterior wall (LVPWd), as well as left atrial end-
systolic diameter were measured in the parasternal LV long
axis view. The maximum basal- and mid-septal WT was
measured in the LV parasternal long-axis view. Basal-
septal to mid-septal WT ratio (WT_Ratio) was calculated
as the basal-septal WT divided by the mid-septal WT. Rela-
tive WT ¼ (IVSd þ LVPWd)/LVEDD was calculated. LV
mass indexed for height to allometric power of 2.7 was esti-
mated by LV cavity dimension and WT at end diastole27:
LV mass (g) ¼ 0.8  [1.04  (LVEDD þ LVPWd þ
IVSd)3(LVEDD3)] þ 0.6. LV ejection fraction was
measured with the biplane Simpson method in the apical
4- and 2-chamber views. Mitral annular plane systolic
72 P.D. Gaudron et al. / Journal of the American Society of Hypertension 10(1) (2016) 70–80excursion was measured as well as tricuspid plane annular
systolic excursion was obtained by M-mode in the apical
4-chamber view.
Pulsed-wave Doppler was performed in the apical
4-chamber view to obtain mitral inflow velocities for LV
filling pattern evaluation. Peak velocity of early (E) and
late (A) diastolic filling and deceleration time of E wave
(DT) were measured as well as the E/A ratio was calcu-
lated. Tissue Doppler early diastolic mitral annular velocity
(E0) was obtained at the septal annular site. If necessary iso-
volumetric relaxation time and pulmonary venous flow was
evaluated and diastolic function was graded according to
recent guidelines.28Figure 1. Screening flowchartThe maximum basal- and mid-septal WT was measured
in the LV parasternal long-axis view. SB was defined as
the basal-septal WT  2 mm thicker than the mid-septal
WT. Patients were divided into two subgroups according
to the presence or absence of SB (SB group and no-SB
group).
Reproducibility of basal- and mid-septal WTwas studied
using Bland and Altman analysis. The same recordings
were used in consecutive 30 subjects (Patient ID 1–30).
Repeated measurements blinded to the initial results were
performed by one investigator (D.L.) to assess intraob-
server variation, and by two investigators (D.L. and
P.D.G.) to obtain interobserver variation.of the study population.
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off-line speckle-tracking derived strain rate imaging with
dedicated software (EchoPAC, version 112, GE, Horten,
Norway). All 2D gray scale images of the standard apical
4-chamber view were recorded with a frame rate of 50 to
80 frames per second. A region of interest was created by
manually outlining the endocardial border at end-systolic
frame on the apical 4-chamber view. The system automat-
ically tracked the tissue within the region and divided the
myocardium into six segments. Segmental and global lon-
gitudinal strain curves were obtained and longitudinal
peak systolic strain was measured in the basal, mid, and
apical segments of the septal and lateral walls.
A standard 12-lead resting ECG was recorded with a pa-
per speed of 50 mm/s and an amplification of 0.1 mV/mm.
A normal axis deviation was defined as the mean electrical
axis between 0 and þ90. Less than 0 was termed a left
axis deviation and greater than þ90 was termed a right
axis deviation. The electrocardiographic voltage criterion
for LV hypertrophy was defined according to Sokolow-
Lyon index: SV1 þ RV5 or RV6 is greater than 3.5 mV.
The ST-segment depression was defined as horizontal or
down-sloping depression 1.0 mm at 80 ms after J-point,
lower than baseline level in at least two leads.29
Exercise ECG was recorded continuously during CET.
ECG was printed every 3 minutes interval during exercise
and at least 5 minutes of recovery while the patient was
sitting on the bicycle. The criteria for ischemia in ECG dur-
ing exercise and recovery were any horizontal or down-
sloping ST-segment depression 1.0 mm at 80 ms after
J-point.30
Continuous variables were presented as mean  standard
deviation and categorical variables as percentages. Differ-
ences on continuous data between two subgroups were
compared using an unpaired Student’s t test or Mann-
Whitney test. Categorical data were compared between
groups using a chi square test or Fisher’s exact test, as
appropriate. The receiver operating characteristic analysis
was performed to evaluate the predictive value of SB for
indicating AH. A lineal regression of the quantitative
parameter of SB (WT_Ratio) associated with the classifica-
tion of AH (normal, high-normal, stage 1, and stage 2 hy-
pertension), as well as a logistic regression analysis of
WT_Ratio associated with AH were conducted, respec-
tively. Statistical significance was defined as P < .05
(two-tailed test). Statistical analysis was performed using
IBM SPSS, version 22 for Windows (SPSS).
Results
Among the 110 study patients, the reasons for the echo-
cardiographic examination included as follows: routine
check-up (n ¼ 82, done in individuals who underwent
check-up prechemotherapy, check-up preoperation, or in
patients with high risk of heart diseases such as high-risklipid levels or smoking), unclear thoracic pain (n ¼ 17),
dizziness or syncope (n ¼ 6), dyspnea (n ¼ 2), unclear
palpitation (n ¼ 1), check-up for living kidney donation
(n ¼ 1), or thoracic trauma (n ¼ 1). The average age was
51 years (range, 22–74 years), and 54% of patients were
male. Clinical and BP characteristics of patients without
and with SB are shown in Table 1. SB was evidenced in
48 (43.6%) patients. Patients with SB were older and had
higher body mass index as compared to patients without
SB. SBP and DBP at rest and during ABPM, as well as
SBP during CET were significantly higher in SB group
than in no-SB group.
Resting BP was elevated in 44 (40%) patients. There
were 12 (19.4%) patients with elevated resting BP in no-
SB group (n ¼ 62), whereas all of them (100%) tested
negative for AH by CET and ABPM suggesting a ‘‘white-
coat’’ hypertension in these12 patients. In SB group
(n ¼ 48), 32 had a resting AH and 2 of 32 (6.25%) patients
with elevated resting BP showed a negative result for AH
by CET and ABPM.
There were 66 (60%) patients with normal resting BP. In
no-SB group, 3 of 50 (6%) patients with normal resting BP
tested positive for AH by CET or ABPM. Conversely, in SB
group, 8 of 16 (50%) patients with normal resting BP was
diagnosed as AH by CET or ABPM. Consequently, 38
(79.2%) patients in SB group were diagnosed as AH by
CET or ABPM. In contrast, in no-SB group, only 59
(95.2%) patients tested negative for AH by CET or ABPM.
During resting BP measurement, there were 15 patients
with high-normal BP in SB group, AH was diagnosed in
7 patients (46.7%) by CET or ABPM. In no-SB group,
high-normal BP was found in 33 patients and only 3
(9.1%) of these patients had positive test for AH by CET
or ABPM.
The diagnostic performance of SB to identify AH is
listed in Table 2. When AH was solely diagnosed by resting
BP, SB was a reasonable predictive sign for AH (sensitivity
73%, specificity 76%). However, when AH was confirmed
by CET or ABPM the echocardiographic SB strongly pre-
dicted clinical AH with a sensitivity of 93% and a speci-
ficity of 86%.
Standard echocardiographic parameters are listed in
Table 3. LVEDD, LV mass indexed (mean, 63 g/m2;
range, 26–95 g/m2), and global systolic function (LV
ejection fraction, mitral annular plane systolic excursion,
tricuspid annular plane systolic excursion) remained
normal and were similar between no-SB group and SB
group. Most patients (98.2%) had normal or slightly
reduced diastolic function (¼ stage abnormal relaxation),
and 2 (1.8%) patients had advanced diastolic dysfunction
(pseudonormal filling pattern). Abnormal relaxation
filling pattern was more frequently found in SB group
than in no-SB group (SB group 63% vs. no-SB group
24%). No patient showed a dynamic LV outflow tract
obstruction.
Table 1
Clinical and blood pressure characteristics
Total No-SB SB P Value
n ¼ 110 n ¼ 62 n ¼ 48
Age, years 51  13 49  13 54  12 .024
Male, n (%) 59 (54%) 32 (52%) 27 (56%) .629
Height, cm 174  9 173  8 174  10 .587
Weight, kg 77  15 73  14 81  15 .014
BMI, kg/m2 25  4 24  4 26  4 .009
BSA, m2 1.90  0.21 1.87  0.20 1.95  0.22 .041
Resting BP (mm Hg)
SBP 129  23 120  15 141  27 <.001
DBP 85  11 81  10 90  11 <.001
24-hour ABPM (mm Hg)
Day SBP 126  13 120  7 132  14 <.001
Day DBP 78  9 76  7 82  10 .001
Night SBP 113  12 109  9 116  22 .055
Night DBP 68  10 65  9 72  11 .001
Cycle ergometer test (mm Hg)
100 W SBP 176  25 164  18 190  26 <.001
100 W DBP 92  12 91  10 95  14 .085
AH defined by CET or ABPM, n (%) 41 (37.3%) 3 (4.8%) 38 (79.2%) <.001
AH defined by resting BP, n (%) 44 (40.0%) 12 (19.4%) 32 (66.7%) <.001
Normal 18 (16.4%) 17 (27.4%) 1 (2.1%)
Prehypertension 48 (43.6%) 33 (53.2%) 15 (31.3%)
Stage 1 hypertension 29 (26.4%) 9 (14.5%) 20 (41.7%)
Stage 2 hypertension 15 (13.6%) 3 (4.8%) 12 (25.0%)
ABPM, ambulatory blood pressure monitoring; AH, arterial hypertension; BMI, body mass index; BP, blood pressure; BSA, body surface
area; CET, cycle ergometer test; DBP, diastolic BP; SB, septal bulge; SBP, systolic BP.
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thicker in SB group (12 mm; range, 9–15 mm) than in no-
SB group (8 mm; range, 5–11 mm; P < .001). WT_Ratio is
a quantitative parameter of SB. Lineal regression analysis
demonstrated a moderate correlation of the WT_Ratio
with the AH classification (normal, high-normal, stage 1,Table 2
Predictive value of the presence of septal bulge for artery
hypertension
AH Defined by
Resting BP
AH Defined
by CET or ABPM
Estimated
Value
95% CI Estimated
Value
95% CI
Sensitivity 0.73 0.57–0.85 0.93 0.79–0.98
Specificity 0.76 0.63–0.85 0.86 0.74–0.92
Positive
predictive
value
0.67 0.51–0.79 0.79 0.65–0.89
Negative
predictive
value
0.81 0.68–0.89 0.95 0.86–0.99
ABPM, ambulatory blood pressure monitoring; AH, arterial hy-
pertension; BP, blood pressure; CET, cycle ergometer test; CI,
confidence interval.and stage 2 hypertension) by resting BP: model-adjusted
R2 ¼ 0.461 for age, gender, and BMI, P < .001. The logis-
tic regression analysis showed a moderately strong relation-
ship between CET or ABPM defined AH and WT_Ratio
(R2 ¼ 0.576) after adjusted for age, gender, and BMI. A
0.1 point increase in the WT_Ratio was associated with
2.3-fold increase in risk of AH (odds ratio 2.32, 95% con-
fidence interval [CI] 1.66–3.23, P < .001, Table 4). The
receiver operating characteristic curves analysis
(Figure 2A/B/C) demonstrated that the diagnostic perfor-
mance of WT_Ratio for AH by CET or ABPM was signif-
icantly better than by resting BP [area under the curve 0.90
(95% CI 0.83–0.96) vs. 0.76 (95% CI 0.66–0.85),
P ¼ .018]. In case of Figure 2C, performance of WT_Ratio
was showed in patients with normal resting BP [area under
the curve 0.78 (95% CI 0.61–0.95), P ¼ .003].
In addition, relative WT was significant different be-
tween no-SB group and SB group too, P ¼ .002. Speckle
tracking–derived longitudinal systolic strain at the basal-
septal segment was significantly lower in SB group than
in no-SB group (14%  4% vs. 17%  4%, P < .001,
Table 5). Figure 3 illustrates the examples of segmental lon-
gitudinal systolic strain curves derived from speckle tracing
imaging in patients with or without SB. As shown in
Figure 4, longitudinal systolic strain at the basal-septal
Table 3
Echocardiographic characteristics
Total No-SB SB P Value
n ¼ 110 n ¼ 62 n ¼ 48
LVEDD, mm 45  6 45  5 45  6 .956
Mid IVSd, mm 8.3  1.3 7.9  1.2 8.7  1.3 .001
LVPWd, mm 8.2  1.1 7.8  1.1 8.6  1.0 <.001
RWT 0.37  0.07 0.35  0.06 0.39  0.07 .002
Basal IVSd, mm 9.8  2.4 8.0  1.2 12.0  1.4 <.001
WT_Ratio 1.18  0.23 1.02  0.07 1.40  0.17 <.001
LVM indexed for height2.7 (g/m2.7) 26.9  6.7 25.6  6.1 28.7  7.2 .021
LAD, mm 33  6 32  5 34  7 .050
LVEF, % 65  7 66  7 63  6 .057
55% 105 (95.5%) 60 (97%) 45 (94%) .651
<55% 5 (4.5%) 2 (3%) 3 (6%) —
MAPSE, mm 13  2 14  2 13  2 .256
TAPSE, mm 24  3 24  3 23  3 .942
SPAP, mmHg 23  7 22  8 24  6 .209
E wave, cm/s 72  21 75  16 68  25 .068
A wave, cm/s 67  15 64  15 70  15 .060
E/A 1.1  0.3 1.2  0.4 1.0  0.3 .002
DT, ms 209  57 199  47 222  66 .036
E0, cm/s 10  4 10  4 9  3 .107
E/E0 8.0  2.7 7.6  2.4 8.4  3.1 .154
Diastolic filling pattern, n (%)
Normal/abnormal relaxation/pseudonormal 63/45/2 (57%/41%/2%) 46/15/1 (74%/24%/2%) 17/30/1 (35%/63%/2%) .001
A, late diastolic peak filling velocity; DT, deceleration time of early diastolic peak velocity; E, early diastolic peak filling velocity; E’,
tissue Doppler early diastolic septal mitral annular velocity; EF, ejection fraction; IVSd, end-diastolic wall thickness of interventricular
septum; LAD, end-systolic left atrial diameter; LV, left ventricle; LVEDD, end-diastolic left ventricular dimension; LVMI, LV mass indexed
to body surface area; LVPWd, end-diastolic thickness of LV posterior wall; MAPSE, average of mitral annular plane systolic excursion
measured at the septal and lateral sites; RA, right atrium; RWT, relative wall thickness; SB, septal bulge; SPAP, systolic pulmonary artery
pressure; TAPSE, tricuspid annular plane systolic excursion; WT_Ratio, basal-septal to mid-septal wall thickness ratio.
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septal WT.
ECG data were similar between groups except that left
axis deviation was more frequently seen in SB group than
in no-SB group (Table 6).
The interobserver absolute bias of basal- and mid-septal
WT was 0.60 mm (95% CI 0.25–0.95) and 0.23 (95% CI
0.02 to 0.49), respectively. The intraobserver absolute
bias of basal- and mid-septal WT was 0.10 mm (95%
CI 0.47 to 0.27) and 0.17 mm (95% CI 0.45 to
0.11), respectively.Table 4
Logistic regression analysis of basal-septal to mid-septal wall thickness
WT_Ratio Chi Square P Value Nagelkerke R
Unadjusted 56.11 <.001 0.545
Adjustedy 57.40 <.001 0.576
ABPM, ambulatory blood pressure monitoring; AH, arterial hypertens
eter test; CI, confidence interval.
* The odds ratio for a 0.1 point change in WT_Ratio.
yAdjusted for age, gender, and BMI.Discussion
In this cross-sectional study, we focused on a patient
population without a history of AH and other cardiac dis-
eases. In these patients, we searched for a SB as an early
sign for cardiac remodeling. The main findings of the study
are as follows: (1) the echocardiographic SB sign strongly
predicted AH with sensitivity of 93% and specificity of
86%; (2) the SB in patients with AH is a very early sigh
for hypertensive heart disease indicating remodeling of
the LV with increasing regional WT and reduced localratio (WT_Ratio) associated with AH defined by CET or ABMP
Square Odds Ratio* 95% CI P Value
2.429 1.767–3.340 <.001
2.319 1.664–3.233 <.001
ion; BMI, body mass index; BP, blood pressure; CET, cycle ergom-
Figure 2. ROC analysis of the basal-septal to mid-septal wall thickness ratio (WT_ratio) for indicating AH defined by (A) resting BP
(upper), by (B) CET or ABPM (lower), or defined by (C) CET/ABPM in patients with normal resting BP. Note that the diagnostic per-
formance of WT_Ratio for AH by CET or ABPM was significantly better than by resting BP (P ¼ .018). ABPM, ambulatory blood
pressure monitoring; AH, arterial hypertension; AUC, area under the curve; BP, blood pressure; CET, cycle ergometer test; ROC,
receiver operating characteristic.
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diagnosis of AH is very unlikely in patients with normal
echocardiographic findings and without a SB sign; and
(4) in all patients with an accidental SB sign during echo-
cardiography, a sophisticated diagnostic work up including
resting BP measurement, ABPM, and CET for a potential
AH should be initiated.
Data from the Framingham Heart study showed that the
overall prevalence of SB was 1.5% in the general popula-
tion.18 Previous studies have suggested that hypertrophy
in the basal portion of the intraventricular septum (ie,
SB) in the elderly may represent a pattern of cardiac hyper-
trophy caused by hypertension.18,31,32 In patients with AH,
development of concentric LV hypertrophy is considered to
be a typical adaptive process during long-lasting pressure
overload.33 Nevertheless, a number of patients with mild-
to-moderate hypertension often exhibit normal WT andTable 5
Longitudinal strain by speckle tracking imaging
Total No-SB SB P Value
n ¼ 110 n ¼ 61 n ¼ 49
Septal wall longitudinal strain (%)
Apical 24  4 24  5 25  4 .823
Mid 20  3 21  3 19  3 .006
Basal 16  4 17  4 14  4 <.001
Lateral wall longitudinal strain (%)
Apical 23  5 23  5 22  5 .412
Mid 21  4 22  3 20  4 .002
Basal 19  4 19  4 18  4 .084
Global longitudinal
strain (%)
20  3 20  3 19  3 .008
SB, septal bulge.LV mass.34 Some early hypertensive patients may only
exhibit myocardial hypertrophy at the basal part of the
septum, but with a normal LV WT elsewhere, thus, LV
mass index might be still normal in these patients. Con-
forming to the aforementioned observations, our data also
demonstrated that echocardiographic SB is frequently de-
tected in AH patients at early disease stage with a high
sensitivity (93%) and specificity (86%). Previous studies
mostly studied established AH patients who had been
suffering from high BP for years and decades. Differing
from these studies, data from our study were derived
from newly diagnosed AH patients who were unaware of
their condition. These early AH patients largely presented
with normal LV mass and normal global systolic and dia-
stolic function except a distinct localized hypertrophy at
the basal septum. Thus, SB seems be a specific localized
structural remodeling in response to the elevated pressure
load before the development of concentric hypertrophy at
the early AH disease journey.
It is known that high-normal BP at resting BP assessment
is indicative of increased risk for progression to hyperten-
sion compared to those with normal BP.35 Nearly half of
the patients with SB (46.9%) were found to have AH by
CET and/or ABPM. In contrast, almost all patients without
SB (90%) had no positive test for AH by CET or ABPM.
SB strongly indicated the presence of AH not only in sus-
tained hypertensive patients but also in ‘‘prehypertensive’’
patients.
It is to note that, of 44 patients with elevated resting BP,
14 patients tested negative for AH by either CET or ABPM
(12 in no-SB group and 2 in SB group). These patients are
clinically defined as ‘‘white-coat’’ hypertension. It is
known that ‘‘white-coat’’ hypertension is a phenomenon
in which patients show elevated BP in a clinical setting
Figure 3. Examples of segmental longitudinal systolic strain curves derived from speckle tracing imaging in patients with (A) or without
(B) septal bulge (SB).
Figure 4. Association between regional longitudinal systolic
strain and regional wall thickness (WT) at the basal-septal
segment. Speckle tracking–derived longitudinal systolic strain
at the basal-septal segment was gradually decreased with
increasing basal-septal WT.
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measurement using a home BP monitoring device is being
increasingly used to differentiate those with ‘‘white-coat’’
hypertension from those with sustained hypertension. Our
data showed a low prevalence of SB in these ‘‘white-
coat’’ hypertension patients. Thus, during clinical BP mea-
surement the presence or absence of an echocardiographic
SB can be a useful feature to distinguish real AH from
‘‘white-coat’’ hypertension.
Masked hypertension is defined as normal resting BP in
the clinic (<140/90 mm Hg), but elevated BP out of the
clinic (ambulatory daytime BP or home BP > 135/85 mm
Hg).36,37 It is known that even masked hypertension can
be associated with end-organ damage.37 Twenty-four–hour
ABPM provides multiple, objective BP measurements in
the patient’s own environment over a full circadian period.
Meanwhile, exercise testing has being increasingly recog-
nized as a useful tool for cardiovascular risk prediction of
asymptomatic patients with normal or borderline BP.38 Ex-
ercise test can be used to evaluate prehypertensive stages, to
characterize hypertension, and to assess tolerance to exer-
cise as well as the efficacy of antihypertensive therapies.39,40
Table 6
Resting and exercise electrocardiography
No-SB SB P Value
n ¼ 62 n ¼ 48
Heart rate, beats/min 69  9 72  11 .210
Sinus rhythm 60 (98%) 48 (100%) .373
LV Sokolow index, mV 1.9  0.7 1.9  0.6 .966
Mean electrical axis .027
Normal axis 45 (73%) 25 (52%)
Left-axis deviation 17 (27%) 23 (48%)
Right-axis deviation 0 (0%) 0 (0%)
ST-segment depression at
rest
0 (0%) 1 (2%) .262
ST-segment depression
during exercise
2 (3%) 4 (9%) .236
LV, left ventricle; SB, septal bulge.
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masked hypertension. Interestingly, 8 (72.7%) of these pa-
tients exhibited SB sign. These findings further support
the diagnostic value of echocardiographic SB sign for AH.
In addition, it proposes that measurement of BP with appro-
priate tools is essential to unmask hypertension.
AH results in a permanent pressure overload of the LV. In
patients with hypertension, the LV myocardium compen-
sates for this increased systolic wall stress by developing
hypertrophy. Regional wall stress of LV wall is inhomoge-
neous according to the irregular curvature within the non-
spheric LV.41 Owing to the largest local radius of the LV
curvature at the basal septum, wall stress is highest there.
Because hypertrophy is directly related to wall stress the
basal septal segment usually develops first the characteristic
bulge. In newly diagnosed hypertensive patients, this basal
SB is especially prominent as the rest of the LV is not yet
hypertrophic.42 Previous studies have shown that hypertro-
phic tissue induced by AH is associated with decreased
myocardial efficiency and perfusion reserve.43 Thus, the
decreased deformation at basal-septal segment in AH (as-
sessed by speckle tracking imaging) might be caused by
myocardial hypertrophy with a suboptimal perfusion of
the subendocardium.44–46
In previous studies, SB was defined as 50% greater than
the thickness of the mid septal wall (mm) at end-diastolic
phase.32 In the present study, we decided to use the strict cri-
terion of a minimal difference of 2 mm in WT as a definition
for SB to be very precise and to avoid missing patients with
this potential imaging sign for hypertension. It is relatively
difficult to measure in clinical routine. However, the present
study was aimed as proof of concept study. Thus, further
larger multicenter studies have to confirm the current find-
ings. As in some patients the SB was quite prominent, we
cannot completely rule out that these hearts suffer from hy-
pertrophic cardiomyopathy.
Screening started from the echocardiographic assessment
in the present study. Thus, the ‘‘real normal’’ populationwas not included in this cohort. The prevalence of SB re-
ported in this cohort therefore did not reflect that of the
general population.
In addition, it is to note that the ABPM procedure and
AH diagnosis criteria in the present study were based on
the JNC 7 report,1 not on the ABPM recommendation of
2013.47 This point needs to be cared by interpredating pre-
sent results.
In clinical practice, echocardiographic SB with a normal
LV mass is often not considered as a pathologic sign by cli-
nicians. Our data suggest that SB is a reliable and sensitive
echocardiographic sign, highly suggestive for AH patients
at early disease stage. Furthermore, SB could be considered
as a sign reflecting the early response to high BP load even
appearing in prehypertensive status. Until now, ABPM and
exercise BP assessment have not been included in the
routine screen for confirming AH because of reimburse-
ment issues, equipment expenses, and time efforts to train
patients in monitor use. The present study suggests that
the presence of SB on echocardiography could be an easy
but helpful indicator in asymptomatic AH patients and
thus to initiate sophisticated diagnostics for AH. Absence
of SB is suggestive of ‘‘white-coat’’ hypertension in pa-
tients with elevated resting BP. In patients with SB sign
but normal resting BP, performing CET and ABPM might
be valuable to detect masked hypertension.
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